These factors explain enrichment of TCA/mitochondrial lesions in specific tumor types (e.g., IDH-mutant glioma/acute myeloid leukemia, SDHx in pheochromocytoma/paraganglioma, and FH-deficient renal cell carcinoma) without implying a universal rule [32,33]. The gene discussed is IDH1; the disease is central nervous system cancer.